PLRZ · Polyrizon Ltd.

Polyrizon Ltd., an Israeli development-stage biotech, focuses on nasal hydrogel technologies addressing unmet needs in allergy and viral protection markets. The C&C platform creates physical barriers against allergens and viruses using seaweed-derived, FDA GRAS polymers, positioned as medical devices rather than drugs to expedite regulatory paths. Leading candidate NASARIX (PL-14) targets allergic rhinitis via 510(k) clearance with identified predicates (Alzair, Nasalease, Bentrio), supported by GMP batch production, positive preclinical blocking data, and ongoing human factors studies; timeline estimates 21-42 months to clearance. PL-16 influenza blocker pursues De Novo Class II classification absent predicates, with preclinical safety underway and clinical trials planned for 2027-2028. T&T platform enables sustained nasal API delivery (corticosteroids, benzodiazepines, naloxone), entering feasibility studies through 2026. Recent Clearmind collaboration explores MEAI neuroplastogen delivery, expanding CNS applications.

Financially, Polyrizon reports no revenue as a pre-commercial entity, with 2025 net loss of $3.3M driven by $2.1M R&D and $4.1M G&A expenses, up significantly from 2024's $1.5M loss amid reverse splits and financings. Cash burn reflects clinical advancement; Dec 31, 2025 cash stands at $1.3M (pro forma $4.3M post-$3M net from April 2026 offerings), plus $10.2M short-term deposits and $6M long-term, yielding $21.4M total assets against $20.9M equity. April 2026 raised $3.5M gross via registered direct (87,777 shares + 190k pre-funded warrants at ~$9) and concurrent PIPE (111k pre-funded + 389k warrants), with Aegis placement fees.

This F-1 registers 499,999 Ordinary Shares (111k from PIPE pre-funded, 389k from Ordinary Share warrants) for resale by Armistice Capital, held via Master Fund with 4.99% ownership cap. Company receives no resale proceeds but up to $3.5M if warrants exercised for cash ($9/share Ordinary, nominal pre-funded); uses for working capital. Shares outstanding rose post-splits to 1.87M as of April 2026 (1.61M at year-end), with dilution from 89k exercised pre-funded warrants reflected pro forma. Nasdaq-listed PLRZ traded at $14.64 on April 22, 2026, implying warrant in-the-money potential.

Key risks center on regulatory uncertainty—FDA rejection of device classifications could force PMA delays—and dilution from 500k share resale amid low float. Israel-based operations face geopolitical risks. Leadership averages 17+ years life sciences experience, backed by scientific advisory board, but as emerging growth/foreign private issuer, reduced disclosures apply. No dividends planned; Israeli law restricts payouts. Investors face pre-revenue biotech risks with barrier tech differentiation, but execution hinges on FDA alignment and cash runway extension via warrant exercises.